Document Detail

Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge.
MedLine Citation:
PMID:  17443130     Owner:  NLM     Status:  MEDLINE    
Prenatal exposure to infections represents a risk factor for the emergence of neuropsychiatric disorders in later life, including schizophrenia and autism. However, it remains essentially unknown whether this association is primarily attributable to prenatal and/or postnatal maternal effects on the offspring. Here, we addressed this issue by dissecting the relative contributions of prenatal inflammatory events and postnatal maternal factors in an animal model of prenatal viral-like infection. Pregnant mice were exposed to the inflammatory agent polyriboinosinic-polyribocytidilic acid (PolyI:C; 5 mg/kg, i.v.) or vehicle treatment on gestation day 9, and offspring born to PolyI:C- and vehicle-treated dams were cross fostered to surrogate rearing mothers that had either experienced inflammatory or sham treatment during pregnancy. We demonstrate that a variety of dopamine- and glutamate-related pharmacological and neuroanatomical disturbances emerge after prenatal immune challenge regardless of whether neonates were raised by vehicle- or PolyI:C-exposed surrogate mothers. However, the adoption of prenatal control animals to immune-challenged surrogate mothers was also sufficient to induce specific pharmacological and neuroanatomical abnormalities in the fostered offspring. Multiple schizophrenia-related dysfunctions emerging after prenatal immune challenge are thus mediated by prenatal but not postnatal maternal effects on the offspring, but immunological stress during pregnancy may affect postpartum maternal factors in such a way that being reared by an immune-challenged surrogate mother can confer risk for distinct forms of psychopathology in adult life.
Urs Meyer; Myriel Nyffeler; Severin Schwendener; Irene Knuesel; Benjamin K Yee; Joram Feldon
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-04-18
Journal Detail:
Title:  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology     Volume:  33     ISSN:  0893-133X     ISO Abbreviation:  Neuropsychopharmacology     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2007-12-11     Completed Date:  2008-02-06     Revised Date:  2011-05-18    
Medline Journal Info:
Nlm Unique ID:  8904907     Medline TA:  Neuropsychopharmacology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  441-56     Citation Subset:  IM    
Laboratory of Behavioural Neurobiology, ETH Zurich, Schwerzenbach, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amidines / therapeutic use
Disease Models, Animal
Exploratory Behavior
Habituation, Psychophysiologic
Maternal Behavior
Mice, Inbred C57BL
Motor Activity / drug effects
Paternal Behavior
Poly I-C / therapeutic use
Pregnancy Complications / psychology
Schizophrenia / etiology*,  immunology
Schizophrenic Psychology
Reg. No./Substance:
0/Amidines; 13217-66-8/2,2'-azobis(2-amidinopropane); 24939-03-5/Poly I-C

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antisense oligodeoxynucleotides for estrogen receptor-beta and alpha attenuate estradiol's modulatio...
Next Document:  D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label ...